<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645098</url>
  </required_header>
  <id_info>
    <org_study_id>IRB11-00532</org_study_id>
    <nct_id>NCT01645098</nct_id>
  </id_info>
  <brief_title>Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy</brief_title>
  <official_title>Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional study on Duchenne muscular dystrophy patients who will be receiving
      sedation for a muscle biopsy as part of another study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Sedation Score of 3-4</measure>
    <time_frame>Immediately prior to incision</time_frame>
    <description>The depth of sedation was judged using the University of Michigan Sedation Scale (UMSS). The score ranges from zero, awake and alert, to four, unarousable. A score of three, deeply sedated, or more was considered to be an appropriate level of sedation for the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Change After Dexmedetomidine Loading Dose</measure>
    <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
    <description>Difference in heart rate from baseline to immediately following infusion of dexmedetomidine loading dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Pressure (MAP) Change After Dexmedetomidine Loading Dose</measure>
    <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
    <description>Change in MAP from baseline measurement to immediately post dexmedetomidine infusion measured via blood pressure cuff.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation Change After Dexmedetomidine Loading Dose</measure>
    <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
    <description>Change in oxygen saturation from baseline measurement to immediately post dexmedetomidine infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EtCO2 Change After Dexmedetomidine Loading Dose</measure>
    <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
    <description>Change in end-tidal carbon dioxide from baseline measurement to immediately post dexmedetomidine infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>1 mg/kg IV, additional doses of 0.5 mg/kg as needed</description>
    <arm_group_label>Dexmedetomidine 1 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.5 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>0.5 mcg/kg/hr IV</description>
    <arm_group_label>Dexmedetomidine 1 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.5 mcg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing a muscle biopsy for IRB11-00203.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph D Tobias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <results_first_submitted>February 4, 2015</results_first_submitted>
  <results_first_submitted_qc>February 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2015</results_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Joseph D. Tobias</investigator_full_name>
    <investigator_title>Chairman, Dept. of Anesthesiology &amp; Pain Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine 1 mcg/kg</title>
          <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine 0.5 mcg/kg</title>
          <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine 1 mcg/kg</title>
          <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine 0.5 mcg/kg</title>
          <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="1.4"/>
                    <measurement group_id="B2" value="8.9" spread="1.9"/>
                    <measurement group_id="B3" value="9.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Sedation Score of 3-4</title>
        <description>The depth of sedation was judged using the University of Michigan Sedation Scale (UMSS). The score ranges from zero, awake and alert, to four, unarousable. A score of three, deeply sedated, or more was considered to be an appropriate level of sedation for the procedure.</description>
        <time_frame>Immediately prior to incision</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 1 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Sedation Score of 3-4</title>
          <description>The depth of sedation was judged using the University of Michigan Sedation Scale (UMSS). The score ranges from zero, awake and alert, to four, unarousable. A score of three, deeply sedated, or more was considered to be an appropriate level of sedation for the procedure.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.3"/>
                    <measurement group_id="O2" value="2.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Change After Dexmedetomidine Loading Dose</title>
        <description>Difference in heart rate from baseline to immediately following infusion of dexmedetomidine loading dose.</description>
        <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 1 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Change After Dexmedetomidine Loading Dose</title>
          <description>Difference in heart rate from baseline to immediately following infusion of dexmedetomidine loading dose.</description>
          <units>BPM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="13"/>
                    <measurement group_id="O2" value="-5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Pressure (MAP) Change After Dexmedetomidine Loading Dose</title>
        <description>Change in MAP from baseline measurement to immediately post dexmedetomidine infusion measured via blood pressure cuff.</description>
        <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 1 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Pressure (MAP) Change After Dexmedetomidine Loading Dose</title>
          <description>Change in MAP from baseline measurement to immediately post dexmedetomidine infusion measured via blood pressure cuff.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="10"/>
                    <measurement group_id="O2" value="5" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Saturation Change After Dexmedetomidine Loading Dose</title>
        <description>Change in oxygen saturation from baseline measurement to immediately post dexmedetomidine infusion.</description>
        <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 1 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation Change After Dexmedetomidine Loading Dose</title>
          <description>Change in oxygen saturation from baseline measurement to immediately post dexmedetomidine infusion.</description>
          <units>percentage of oxygen</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EtCO2 Change After Dexmedetomidine Loading Dose</title>
        <description>Change in end-tidal carbon dioxide from baseline measurement to immediately post dexmedetomidine infusion.</description>
        <time_frame>Baseline to immediately post dexmedetomidine infusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 1 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
          </group>
        </group_list>
        <measure>
          <title>EtCO2 Change After Dexmedetomidine Loading Dose</title>
          <description>Change in end-tidal carbon dioxide from baseline measurement to immediately post dexmedetomidine infusion.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="5"/>
                    <measurement group_id="O2" value="2" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine 1 mcg/kg</title>
          <description>Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine 0.5 mcg/kg</title>
          <description>Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine: 0.5 mcg/kg/hr IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marco Corridore, MD</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>614-722-4200</phone>
      <email>Marco.Corridore@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

